P190  Secukinumab improves back pain, morning stiffness, fatigue and physical function in tumour necrosis factor inhibitor-naive patients with non-radiographic axial spondyloarthritis: results from a randomised controlled Phase 3 study

Conclusion Secukinumab provided clinically meaningful improvement in back pain, morning stiffness, fatigue and physical function in TNFi-naive patients with nr-axSpA over 52 weeks.Disclosure H. Marzo-Ortega: Consultancies; H.M-O. is a consultant for AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer and UCB. Member of speakers ’ bureau; H.M-O. is a member of speakers' buraeu for AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, Takeda and UCB. Grants/research support; H.M-O. has received research support from Janssen and Novartis.A. Deodhar: Consultancies; A.D. is a consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, GlaxoSmithKline, Janssen, Novartis, Pfizer and UCB. Grants/research support; A.D. has received grant/research support from AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer and UCB.R. Alonso Blanco: Consultancies; R.A.B. has received consultancy fees from AbbVie, Pfizer, Roche, Bristol Myers Squibb, Janssen, UCB Pharma and MSD. Member of speakers ’ bureau; R.A.B. is a member of the speakers' bureau for AbbVie, Pfizer, Roche, Bristol Myers Squibb, Janssen, UCB Pharma, MSD and Lilly. Grants/research support; R.A.B. has received grant/research support from AbbVie, MSD and Roche.H. Kameda: Consultancies; H.K. is a consultant for AbbVie, Asahi-Kasei, Astellas, Eli Lilly, Gilead Sciences, Janssen, Novartis, Sanofi and UCB. Member of speakers ’ bureau; H.K. has received speakers' bureau fees from: AbbVie, Asahi-Kasei, BMS, Chu...
Source: Rheumatology - Category: Rheumatology Source Type: research